Berger Manon, Degey Manon, Leblond Chain Jeanne, Maquoi Erik, Evrard Brigitte, Lechanteur Anna, Piel Géraldine
Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liege, 4000 Liège, Belgium.
University of Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, F-33000 Bordeaux, France.
Pharmaceutics. 2023 Feb 10;15(2):597. doi: 10.3390/pharmaceutics15020597.
Polyethylene glycol (PEG) is used in Lipid Nanoparticles (LNPs) formulations to confer stealth properties and is traditionally anchored in membranes by a lipid moiety whose length significantly impacts the LNPs fate in vivo. C18 acyl chains are efficiently anchored in the membrane, while shorter C14 lipids are quickly desorbed and replaced by a protein corona responsible for the completely different fate of LNPs. In this context, a method to predict the biological behavior of LNPs depending on the lipid-PEG dissociation was developed using the Nanoparticle Tracking Analysis (NTA) method in serum. Two formulations of siRNA-containing LNPs were prepared including CSL3 or SM-102 lipids and were grafted with different lipids-PEG (C18, C14 lipids-PEG, and Ceramide-PEG). The impact of the lipid-PEG on the interactions between LNPs and serum components was demonstrated by monitoring the mean particle size and the concentration over time. In vitro, these formulations demonstrated low toxicity and efficient gene knockdown on tumor MDA-MB-231 cells, but serum was found to significantly impact the efficiency of C18-PEG-based LNPs, while it did not impact the efficiency of C14-PEG-based LNPs. The NTA method demonstrated the ability to discriminate between the behaviors of LNPs according to serum proteins' interactions. CSL3 lipid and Cer-PEG were confirmed to have promise for LNP formulation.
聚乙二醇(PEG)用于脂质纳米颗粒(LNP)制剂以赋予其隐身特性,传统上它通过脂质部分锚定在膜中,该脂质部分的长度会显著影响LNP在体内的命运。C18酰基链能有效地锚定在膜中,而较短的C14脂质会迅速解吸并被蛋白质冠层取代,这导致了LNP完全不同的命运。在此背景下,利用纳米颗粒跟踪分析(NTA)方法在血清中开发了一种根据脂质-PEG解离来预测LNP生物学行为的方法。制备了两种含siRNA的LNP制剂,包括CSL3或SM-102脂质,并接枝了不同的脂质-PEG(C18、C14脂质-PEG和神经酰胺-PEG)。通过随时间监测平均粒径和浓度,证明了脂质-PEG对LNP与血清成分之间相互作用的影响。在体外,这些制剂对肿瘤MDA-MB-231细胞表现出低毒性和高效的基因敲低作用,但发现血清会显著影响基于C18-PEG的LNP的效率,而对基于C14-PEG的LNP的效率没有影响。NTA方法证明了能够根据与血清蛋白的相互作用来区分LNP的行为。CSL3脂质和Cer-PEG被证实有望用于LNP制剂。